Abstract
Objective: Pregnancy-associated plasma protein-A (PAPP-A) promotes insulin-like growth factor (IGF) pathway activity, which directly correlates to ovarian cancer (OC) tumorigenesis. Because inhibition of PAPP-A with a novel monoclonal antibody to PAPP-A (mAb-PA) had preliminary activity in an OC patient-derived xenograft (PDX) model, we hypothesize that adding mAb-PA to carboplatin/paclitaxel (CP) would partially overcome platinum resistance in a panel of OC PDX.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
